That is why I have below the market buy orders in here, during this news hiatus on the covid19 test. If I can add more around the price that Conifer just bought in, I will very likely clean up over my holding period.
RE: Could GDR rise significantly Friday?12 Jun 2020 06:51
The issue with testing the community now is not, who has the gold standard test. It is all about who can supply the test kit or product to the masses with the fastest turnaround time and the cheapest, that also satisfies the minimum specificity and sensitivity standards laid down by the regulatory authorities. Govts now want scale but to limit expense, as they have enough other issues in their plates to deal with, like the economy.
So, I learned this evening that Avacta will be filing an IND for AV6000 in the USA, "very shortly".
Given that in the afternoon session, AS said that Avacta has enough funds now to progress AV6000 to a UK clinical P1 trial, this suggests to me that a partner may be forthcoming soon to assist/expedite the US trials.
And, as expected, AS reiterated that he has "a high level of confidence" that Avacta can deliver a working LFD for Covid19.
Generally, I thought he handled all the questions very confidently and professionally. Ruane, who, incidentally, have been in discussions with AS for a year now, apparently, would be proud of him.
You guys really have to understand munchbox54's MO. He does the same stuff all over the AIM shares he's interested in. Hoping to scare a few into selling, and hoping to elicit some positive reasons to buy that he hasn't figured out for himself. Make no mistake, he wants in, but at a lower price.
longrun..., It's not a question of needing to free up more shares, as you put it. Rarely does management think in such terms. If they decide that the company in its current financial shape, and with due regard to future business financing requirements, needs extra equity capital, then they might go for another placing. That would have a secondary effect of creating more share liquidity. But the GDR directors would need to take into account the recency of their last placing, the effect on the share price and the stated fact that the last placing would take care of the immediate manufacturing needs for he initial production of 6mn GeneDrive96 kits. Any more fresh capital raised now would need a very, very good reason why.
I found this article on t w i t t e r today, very interesting and a great reminder of how long term investors make BIG money. And the clear message for diagnostic companies is that it is still an unexplored, undervalued theme in the healthcare sector.